Anika Therapeutics (ANIK) Misses Q2 EPS by 5c

Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of ($0.13), $0.05 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $28.22 million versus the consensus estimate of $28.15 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Golden Spike Resources plans name change, share consolidation and C$500K raise
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance